| 2.36 0.22 (10.28%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.44 |
1-year : | 4.02 |
| Resists | First : | 2.95 |
Second : | 3.44 |
| Pivot price | 2.52  |
|||
| Supports | First : | 2.43 |
Second : | 2.1 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.58 |
| MA(100) : | 3 |
MA(250) : | 3.76 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43 |
D(3) : | 29.6 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 7.17 | Low : | 2.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MDGS ] has closed below upper band by 37.3%. Bollinger Bands are 40% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.37 | 2.37 - 2.39 |
| Low: | 2.33 - 2.34 | 2.34 - 2.35 |
| Close: | 2.33 - 2.36 | 2.36 - 2.38 |
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Thu, 18 Apr 2024
Medigus Ltd. will Change its Ticker to XYLO from MDGS - Marketscreener.com
Mon, 15 Apr 2024
Medigus Ltd. (NASDAQ:MDGS) Short Interest Down 17.6% in March - Defense World
Mon, 15 Apr 2024
Medigus (NASDAQ:MDGS) vs. Nevro (NYSE:NVRO) Financial Analysis - Defense World
Tue, 09 Apr 2024
Medigus Announces Corporate Rebranding Changes Name to Xylo Technologies Ltd. to Reflect Core Values of its ... - Yahoo Finance Australia
Wed, 27 Mar 2024
Medigus: Revoltz Initiates on Exclusive Distribution Agreement of $2.7 Million in Revenues and Completes the ... - GlobeNewswire
Tue, 19 Mar 2024
Medigus Unveils Wireless EV Charging in Automated Parks - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -8.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.67 |
| Profit Margin | -13.1 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -6.7 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 52.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 58.34 |
| EBITDA (p.s.) | -3.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0.04 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|